FDA's Overreach on Compounded Peptides BPC157, TB500, GHK Cu FDA The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: The peptide with big claims and scant evidence STAT Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law